-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
May 10, 2020 / / SARS-CoV-2 appeared in 2019 as a pathogen leading to the new pandemic viral disease COVID-19.
the lack of approved treatments, the pandemic demonstrates the urgent need for a safe, broad-spectrum antiviral response to SARS-CoV-2 and future CoV.
Researchers from the University of North Carolina at Chapel Hill and others recently reported that a monophosphate methylamine pre-drug for rydesiwe-adenosine analogoids can strongly inhibit SARS-CoV-2 replication in human lung cells and main gas path epithelial cells (EC50 s 0.01 m).
the relatively weak inhibition of viral activity observed by researchers in the Vero E6 cell experiment, which the researchers believe is due to the cell's weak ability to metabolize redsivir.
photo source: BioRxiv To quickly assess efficacy in the body, researchers designed a target for embedded SARS-CoV virus, an RNA polymerase that encodes SARS-CoV-2 that relies on RNA.
in mice infected with the virus, Redsyvir treatment significantly reduced lung viral load and improved lung function compared to the control group.
, these data showed that Redsyve had a strong inhibitory activity against SARS-CoV-2 in vitro, providing a basis for further clinical trials of COVID-19 therapy.
this is the first time in 204 continuous and primitive human lung cultures that the effective inhibition of SARS-CoV-2 has been strictly demonstrated, and the first study to show that Redsiway has an effective inhibitory effect on SARS CoV-2 in mice.
results were published recently on the preprinted platform bioRxiv under the title "Remdesivir potentlys reseds SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice".
() Reference: Andrea J Pruijssers et al. Remdesivir potently res SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.04.27.06427.
